The Clinical and Immunological Effects of Pru p 3 Slit on Peach and Peanut Tolerance in Patients with Systemic Allergic Reactions.
Saturday, March 5, 2016: 2:00 PM
Room 408B (Convention Center)
Francisca Gómez, MD, PhD, , , , , , , , , , ,
Rationale: The peach non-specific lipid transfer protein (nsLTP), Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently accompanied with other allergies as peanut. Specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance. The aim is evaluate peach and peanut tolerance and immunological changes after one year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut.

Methods: Forty-eight peach allergic patients, 36 treated with SLIT and 12 non-treated, were monitored for 12 months. Treated patients were sub-classified as peanut allergic (Group A), sensitized (Group B) or tolerant (Group C). SLIT efficacy was evaluated by skin test reactivity and food tolerance. Immunological changes were evaluated by monitoring sIgE and sIgG4 levels and basophil reactivity.

Results: After one year of SLIT, the wheal area in SPT significantly decreased and there was a significant increase in the amount of peach tolerated in treated patients (p<0.001). Patients in Group A showed a significant decrease in peanut SPT wheal area and an increase in amount of peanut tolerated (p<0.001). Immunological changes were observed in treated patients only, with a significant decrease of sIgE and a parallel increase of sIgG4, sIgG4/sIgE and basophil reactivity for both Pru p 3 and Ara h 9.

Conclusions: After one year Pru p 3 SLIT induces both clinical and immunological changes not only for peach but also for other food allergens relevant in the induction of severe reactions such as peanut.